epidermal growth factor receptor (EGFR)

More people in the U.S. die from breast cancer than non-small cell lung cancer (NSCLC), colorectal cancer, prostate cancer combined. In pre-clinical trials, oral gefitinib gefitinib growth was inhibited expression of non-small cell lung cancer tumor cells of the epidermal growth factor receptor (EGFR) signal transduction mediator and phase 1 trials have demonstrated a small portion of non-small cell experience in the development of lung cancer patients after chemotherapy both reduce the symptoms of lung cancer with gefitinib gefitinib and radiation oncology contraction.